Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
BioMarin axes 4 candidates, centers R&D around 3 assets
BioMarin is prioritizing three of its “most productive” assets, leaving four candidates on the wayside in a move expected to save up to $60 million.
Gabrielle Masson
Apr 25, 2024 10:10am
As pharma eyes shiny obesity drugs, Vertex tops orphan drug list
Apr 24, 2024 12:01am
J&J funds Rallybio in risk-busting rare pregnancy disease pact
Apr 10, 2024 4:00pm
Amylyx stock slips 6% after phase 2 rare disease data drop
Apr 10, 2024 2:48pm
ACC: Efficacy ticks down a smidge for Ionis' metabolic drug
Apr 7, 2024 9:45am
J&J targets rare maternal-fetal disease: 'We're going for this'
Apr 2, 2024 11:23am